Development of Sjögren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C

J Gastroenterol. 1996 Oct;31(5):723-7. doi: 10.1007/BF02347624.

Abstract

A 63-year-old woman with type C chronic active hepatitis developed Sjögren's syndrome after being treated with recombinant interferon-alpha-2b. After 3 months' interferon-alpha administration, serum levels of gamma-globulin (4.5 g/dl) and titers of antinuclear and anti-SS-A antibodies were greatly increased, anti-SS-B antibody appeared, and the erythrocyte sedimentation rate was elevated. Although no xerostomia was exhibited, the patient experienced conjunctival dryness. Schirmer's test showed reduced lacrimal gland function and a gum test showed reduced salivary gland function. Sialography revealed scattered pools of retained contrast media with a diameter of around 1-2 mm. Based on these findings, a diagnosis of Sjögren's syndrome was made. This present case may provide important information regarding the pathogenesis of Sjögren's syndrome.

Publication types

  • Case Reports

MeSH terms

  • Biopsy, Needle
  • Chronic Disease
  • Diagnosis, Differential
  • Female
  • Hepatitis C / drug therapy*
  • Hepatitis C / pathology
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Interferon-alpha / therapeutic use
  • Middle Aged
  • Recombinant Proteins
  • Sjogren's Syndrome / chemically induced*
  • Sjogren's Syndrome / diagnosis

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins